{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:57:49Z","timestamp":1780372669485,"version":"3.54.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jbspin.2023.105592","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:32:23Z","timestamp":1684283543000},"page":"105592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Recommendations for assessing the risk of cardiovascular disease and venous thromboembolism before the initiation of targeted therapies for chronic inflammatory rheumatic diseases"],"prefix":"10.1016","volume":"90","author":[{"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hecquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Daien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Elalamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Prati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Hugues","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Elise","family":"Truchetet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Sellam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Molto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2023.105592_bib0380","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/ard.2008.094151","article-title":"Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation","volume":"68","author":"van Halm","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0385","first-page":"7005","article-title":"Venous thromboembolism risk in rheumatoid arthritis patients: a systematic review and updated meta-analysis","volume":"25","author":"Hu","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jbspin.2023.105592_bib0390","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0395","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105592_bib0400","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2022-eular.2686","article-title":"Comparison of major cardiovascular and thromboembolic events in safety reports between rheumatoid arthritis patients treated with JAK inhibitors versus anti-TNF: results from VigiBase","volume":"81","author":"Montastruc","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0405","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00228-022-03402-2","article-title":"JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study","volume":"78","author":"Gouverneur","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jbspin.2023.105592_bib0420","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0425","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.semarthrit.2016.10.007","article-title":"Mortality profile of patients with rheumatoid arthritis in France and its change in 10 years","volume":"46","author":"Avouac","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105592_bib0430","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/ard.2010.143396","article-title":"The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study","volume":"70","author":"Lindhardsen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0435","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1136\/ard.2009.122226","article-title":"Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity","volume":"69","author":"Solomon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0440","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.semarthrit.2012.02.008","article-title":"No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis-a retrospective cohort study using routine data","volume":"4","author":"Brophy","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105592_bib0445","doi-asserted-by":"crossref","first-page":"105122","DOI":"10.1016\/j.jbspin.2020.105122","article-title":"Risk of venous thromboembolism in rheumatoid arthritis","volume":"88","author":"Ketfi","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2023.105592_bib0450","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/acr.22039","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2023.105592_bib0455","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/2012.jama.11741","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization","volume":"308","author":"Holmqvist","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2023.105592_bib0460","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1136\/annrheumdis-2013-203380","article-title":"Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study","volume":"73","author":"Chung","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0465","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/keaa262","article-title":"The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2023.105592_bib0470","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/annrheumdis-2020-218419","article-title":"Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden","volume":"80","author":"Molander","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0475","doi-asserted-by":"crossref","first-page":"e001618","DOI":"10.1136\/rmdopen-2021-001618","article-title":"Risk factors for venous thromboembolism and atherosclerotic cardiovascular disease: do they differ in patients with rheumatoid arthritis?","volume":"7","author":"Ozen","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2023.105592_bib0480","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s00296-022-05121-4","article-title":"Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time-averaged DAS28CRP: a nested case-control study","volume":"42","author":"Yoshimura","year":"2022","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2023.105592_bib0485","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1136\/annrheumdis-2012-201669","article-title":"The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study","volume":"72","author":"Choi","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0490","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/annrheumdis-2016-209315","article-title":"Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?","volume":"76","author":"Eriksson","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-9-1","article-title":"Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study","volume":"9","author":"Ramagopalan","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.jbspin.2023.105592_bib0500","first-page":"171","article-title":"Autoimmune diseases and venous thromboembolism: a review of the literature","volume":"2","author":"Zoller","year":"2012","journal-title":"Am J Cardiovasc Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0505","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2018-214388","article-title":"Risk of venous thromboembolism in ankylosing spondylitis: a general population-based study","volume":"78","author":"Avina-Zubieta","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0510","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.semarthrit.2021.04.008","article-title":"The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis","volume":"51","author":"Damian","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105592_bib0515","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13075-021-02703-8","article-title":"The association between psoriatic arthritis and venous thromboembolism: a population-based cohort study","volume":"24","author":"Gazitt","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2023.105592_bib0520","doi-asserted-by":"crossref","first-page":"e001392","DOI":"10.1136\/rmdopen-2020-001392","article-title":"Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study","volume":"6","author":"Galloway","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2023.105592_bib0525","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jid.2017.10.024","article-title":"Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study","volume":"138","author":"Ogdie","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jbspin.2023.105592_bib0530","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-017-1315-z","article-title":"Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study","volume":"19","author":"Bengtsson","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2023.105592_bib0535","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1163\/15685590051129869","article-title":"Hypercoagulability in various autoimmune diseases: no association with factor V Leiden mutation","volume":"30","author":"Regeczy","year":"2000","journal-title":"Haematologia (Budap)"},{"key":"10.1016\/j.jbspin.2023.105592_bib0540","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jbspin.2023.105592_bib0545","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH12-07-0508","article-title":"The use of weighted and scored risk assessment models for venous thromboembolism","volume":"108","author":"Spyropoulos","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jbspin.2023.105592_bib0550","doi-asserted-by":"crossref","first-page":"e227S","DOI":"10.1378\/chest.11-2297","article-title":"Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Gould","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jbspin.2023.105592_bib0555","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1111\/j.1538-7836.2010.04044.x","article-title":"A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score","volume":"8","author":"Barbar","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jbspin.2023.105592_bib0560","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1378\/chest.10-1944","article-title":"Predictive and associative models to identify hospitalized medical patients at risk for VTE","volume":"140","author":"Spyropoulos","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.jbspin.2023.105592_bib0565","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/ard-2022-223302","article-title":"Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis","volume":"82","author":"Solomon","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0570","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0575","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105592_bib0580","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0585","doi-asserted-by":"crossref","first-page":"105344","DOI":"10.1016\/j.jbspin.2022.105344","article-title":"2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis","volume":"89","author":"Wendling","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2023.105592_bib0590","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.1505","article-title":"TNF inhibitors are associated with a reduced risk of venous thromboembolism compared to csDMARDs in RA patients","author":"Schaefer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0595","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0600","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1111\/bcp.15361","article-title":"Thromboembolic events in Janus kinase inhibitors: a pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System","volume":"88","author":"Dong","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jbspin.2023.105592_bib0605","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.116.024507","article-title":"Association of traditional cardiovascular risk factors with venous thromboembolism: an individual participant data meta-analysis of prospective studies","volume":"135","author":"Mahmoodi","year":"2017","journal-title":"circulation"},{"key":"10.1016\/j.jbspin.2023.105592_bib0610","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/0003-4819-142-4-200502150-00005","article-title":"The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial","volume":"142","author":"Anthonisen","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2023.105592_bib0615","doi-asserted-by":"crossref","first-page":"105319","DOI":"10.1016\/j.jbspin.2021.105319","article-title":"Dietary recommendations of the French Society for Rheumatology for patients with chronic inflammatory rheumatic diseases","volume":"89","author":"Daien","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2023.105592_bib0620","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/annrheumdis-2013-203291","article-title":"Individualised exercise improves endothelial function in patients with rheumatoid arthritis","volume":"73","author":"Metsios","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0625","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/art.24891","article-title":"Effects of high-intensity resistance training in patients with rheumatoid arthritis: a randomized controlled trial","volume":"61","author":"Lemmey","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105592_bib0630","first-page":"676","article-title":"Mediterranean diet for primary prevention of cardiovascular disease","volume":"369","author":"Estruch","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105592_bib0640","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0645","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0650","article-title":"MACE and VTE across upadacitinib clinical trial programs in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [abstract]","volume":"74","author":"Charles-Schoeman","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105592_bib0655","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/M20-0347","article-title":"Should you treat this acutely ill medical inpatient with venous thromboembolism chemoprophylaxis? Grand rounds discussion from Beth Israel Deaconess Medical Center","volume":"172","author":"Kanjee","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2023.105592_bib0660","article-title":"The risk of venous thromboembolic events in patients with RA aged\u226550 years with\u22651 cardiovascular risk factor: results from a phase 3b\/4 randomized safety study of tofacitinib vs. tnf inhibitors [abstract]","volume":"73","author":"Charles-Schoeman","year":"2021","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105592_bib0665","doi-asserted-by":"crossref","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15,000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2023.105592_bib0670","article-title":"Exploratory analysis of filgotinib safety data in patients with moderately to severely active RA and an increased risk of cardiovascular events: data from phase 2 and 3 clinical trials [abstract]","volume":"74","author":"Buch","year":"2022","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105592_bib0675","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105592_bib0680","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105592_bib0685","doi-asserted-by":"crossref","first-page":"e002012","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2023.105592_bib0690","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2023.105592_bib0695","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2023.105592_bib0700","article-title":"Outcomes of filgotinib in patients with RA aged\u226565 years: a post hoc subgroup analysis of phase 2 and 3 clinical trials and ongoing long-term extensions [abstract]","volume":"74","author":"Buch","year":"2022","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105592_bib0705","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105592_bib0710","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1093\/rheumatology\/keaa858","article-title":"Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway","volume":"60","author":"Fitton","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2023.105592_bib0715","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1093\/rheumatology\/keaa810","article-title":"Influence of inflammatory and non-inflammatory rheumatic disorders on the clinical and biological profile of type-2 diabetes","volume":"60","author":"Avouac","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2023.105592_bib0720","first-page":"451","article-title":"Assessing the risk of recurrent venous thromboembolism--a practical approach","volume":"11","author":"Fahrni","year":"2015","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jbspin.2023.105592_bib0725","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","volume":"2","author":"Schunemann","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jbspin.2023.105592_bib0730","first-page":"CD004318","article-title":"Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery","volume":"8","author":"Felder","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jbspin.2023.105592_bib0735","first-page":"CD004179","article-title":"Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair","volume":"3","author":"Forster","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jbspin.2023.105592_bib0740","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/SLA.0000000000000340","article-title":"A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer","volume":"259","author":"Vedovati","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.jbspin.2023.105592_bib0745","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/DCR.0000000000000982","article-title":"The American Society of Colon and Rectal Surgeons Clinical Practice Guideline for the prevention of venous thromboembolic disease in colorectal surgery","volume":"61","author":"Fleming","year":"2018","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.jbspin.2023.105592_bib0750","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40744-022-00505-1","article-title":"Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther."}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X23000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X23000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:31:55Z","timestamp":1761150715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X23000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1297319X23000714"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2023.105592","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for assessing the risk of cardiovascular disease and venous thromboembolism before the initiation of targeted therapies for chronic inflammatory rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2023.105592","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"105592"}}